Clinical Trial Detail

NCT ID NCT01767194
Title Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Monoclonal Antibody Ch14.18 in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

neuroblastoma

Therapies

Dinutuximab

Temsirolimus

Irinotecan + Temozolomide

Age Groups: child

No variant requirements are available.